175 related articles for article (PubMed ID: 20373364)
1. Biliary physiology and disease: reflections of a physician-scientist.
Paumgartner G
Hepatology; 2010 Apr; 51(4):1095-106. PubMed ID: 20373364
[TBL] [Abstract][Full Text] [Related]
2. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
3. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
4. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
[TBL] [Abstract][Full Text] [Related]
5. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
[TBL] [Abstract][Full Text] [Related]
6. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
8. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid for chronic liver diseases.
Podda M; Ghezzi C; Battezzati PM; Bertolini E; Crosignani A; Petroni ML; Zuin M
J Clin Gastroenterol; 1988; 10 Suppl 2():S25-31. PubMed ID: 3062082
[TBL] [Abstract][Full Text] [Related]
10. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
13. Clinical perspective on the treatment of gallstones with ursodeoxycholic acid.
Salen G
J Clin Gastroenterol; 1988; 10 Suppl 2():S12-7. PubMed ID: 3062079
[TBL] [Abstract][Full Text] [Related]
14. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
[TBL] [Abstract][Full Text] [Related]
15. [Molecular mechanisms of bile formation and cholestatic diseases].
Poupon R
Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
[TBL] [Abstract][Full Text] [Related]
16. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
17. [Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)].
Keizman D; Goldiner I; Leikin-Frenkel A; Konikoff FM
Harefuah; 2008 Apr; 147(4):344-9, 373, 372. PubMed ID: 18686819
[TBL] [Abstract][Full Text] [Related]
18. [Pathophysiology of cholestasis: correlation between bile acid metabolism and liver damage].
Stiehl A
Z Gastroenterol; 1992 Mar; 30 Suppl 1():46-8. PubMed ID: 1449016
[TBL] [Abstract][Full Text] [Related]
19. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration.
Crosignani A; Podda M; Battezzati PM; Bertolini E; Zuin M; Watson D; Setchell KD
Hepatology; 1991 Dec; 14(6):1000-7. PubMed ID: 1959845
[TBL] [Abstract][Full Text] [Related]
20. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
